| [1] |
Maroun CR,Rowlands T.The Met receptor tyrosine kinase:a key player in oncogenesis and drug resistance[J].Pharmacol Ther,2014,142(3):316-338.
|
| [2] |
Cui JJ.Targeting receptor tyrosine kinase MET in cancer:small molecule inhibitors and clinical progress[J].J Med Chem,2014,57(11):4427-4453.
|
| [3] |
Giordano S,Columbano A.Met as a therapeutic target in HCC:facts and hopes[J].Hepatol,2014,60(2):442-452.
|
| [4] |
Masami H,Masahiro S,Takashi,et al.Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension[J].Endocrinology,2005,146(11):4682-4689.
|
| [5] |
Vaupel P.The role of hypoxia-induced factors in tumor progression[J].Oncologist,2004, 9(5):10-17.
|
| [6] |
Jeffrey A,Kreshnik Z,Tetsuya M,et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J].Science,2007,316(5827):1039-1043.
|
| [7] |
Alexa BT,Kreshnik Z,Wu YL,et al.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC[J].Cancer Cell,2010,17(1):77-88.
|
| [8] |
Ted LU,Torsten H,Sheila JM.Discovery of small molecule c-Met inhibitors:evolution and profiles of clinical candidates[J].Anti-Cancer Agents Med Chem,2010,10:7-27.
|
| [9] |
Koenig M,Cui JR,Chen WC,et al.Indolinone hydrazides as c-met inhibitors:US,WO 2005005378 A2[P].2003-02-07[2014-10-29] .
|
| [10] |
Vojkovsky T,Koenig M.Tetracyclic compounds as c-met inhibitors:US,WO 2005004808A2[P].2005-01-20[2014-10-29] .
|
| [11] |
Cui JJ,Michele M,Mitchell N,et al.Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor(c-MET)protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3] triazolo[4,5-b] pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol(PF-04217903)for the treatment of cancer[J].J Med Chem,2012,55(18):8091-8109.
|
| [12] |
Cui JJ,Hong S,Michelle TD,et al.Lessons from(S)-6-(1-(6-(1-methyl-1H-pyrazol -4-yl)-[1,2,4] triazolo[4,3-b] pyridazin-3-yl)ethyl )quinoline(PF-04254644),an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats[J].J Med Chem,2013,56(17):6651-6665.
|
| [13] |
Peters S,Adjei AA.MET:a promising anticancer therapeutic target[J].Nat Rev Clin Oncol,2012,9(6):314-326.
|
| [14] |
Sharon D,Jason B,Thomas P,et al.Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications[J].Drug Metab Dispos,2010,38(8):1277-1285.
|
| [15] |
Byung HP,Kyung HJ,Yun SM,et al.KRC-327,a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity[J].Cancer Lett,2013,331(2):158-166.
|
| [16] |
Albrecht BK,Harmange JC,Bauer D,et al.Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase[J].J Med Chem,2008,51(10),2879-2882.
|
| [17] |
Christiane MB,Alessandro AB,Brian KA,et al.Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors[J].Bioorg Med Chem Lett,2012,22(12):4089-4093.
|
| [18] |
Neru M, Jeay S, Li YZ, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity[J].Mol Cancer Ther,2010,9(6):1544-1553.
|
| [19] |
Gretchen MS,Chen XT,David KW,et al.Identification of pyrrolo[2,1-f][1,2,4] triazine-based inhibitors of Met kinase[J].Bioorg Med Chem Lett,2008,18(6):1945-1951.
|
| [20] |
Cai ZW,Wei DN,Gretchen M,et al.Discovery of orally active pyrrolopyridine-and aminopyridine-based Met kinase inhibitors[J].Bioorg Med Chem Lett,2008,18(11):3224-3229.
|
| [21] |
Lu W,Ai J,Shen YY,et al.SOMCL-863,a novel,selective and orally bioavailable small-molecule c-Met inhibitor,exhibits antitumor activity both in vitro and in vivo[J].Cancer Lett,2014,351(1):143-150.
|
| [22] |
Craig AZ,Jay PT,Lisa DA,et al.2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines[J].Bioorg Med Chem Lett,2011,21(2):660-663.
|
| [23] |
Alessandro F,Francesco C,Andrea K,et al.Identification of new aminoacid amides containing the imidazo[2,1-b] benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling[J].Eur J Med Chem,2012,47(1):239-254.
|
| [24] |
Hong SW,Jung KH,Byung HP,et al.KRC-408,a novel c-Met inhibitor,suppresses cell proliferation and angiogenesis of gastric cancer[J].Cancer Lett,2013,332(1):74-82.
|
| [25] |
He CX, Ai J, Xing WQ, et al. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells[J].Acta Pharmacol Sin,2014,35(1):89-97.
|
| [26] |
Kang ST,Kim EY,Raghavendra A,et al.Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors[J].Bioorg Med Chem Lett,2014,24:5093-5097.
|
| [27] |
Joanne VA,Catherine B,Kevin B,et al.The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach[J].Bioorg Med Chem Lett,2011,21(18):5224-5229.
|
| [28] |
Xu JM,Ai J,Liu S,et al.Design and synthesis of 3,3′-biscoumarin-based c-Met inhibitors[J].Org Biomol Chem,2014,12(22):3721-3734.
|
| [29] |
Liu XD,Wang Q,Yang GJ,et al.A novel kinase inhibitor,INCB28060,blocks c-MET-dependent signaling,neoplastic activities,and cross-talk with EGFR and HER-3[J].Clin Cancer Res,2011,17(22):7127-7138.
|
| [30] |
Friedhelm B,Bettina F,Manja FH,et al.EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors[J].Clin Cancer Res,2013,19(11):2941-2951.
|
| [31] |
Mohammadi M,Froum S,Hamby JM,et al.Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain[J].MBO J,1998,17(20):5896-5904.
|
| [32] |
Alex K,Casie R,Kim LR,et al.Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia[J].Nat Med,2012,18(7):1118-1122.
|
| [33] |
Marta PR,Elizabeth A,James H,et al.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J].Cancer Cell,2009, 15(3):220-231.
|
| [34] |
Barbara S, Toshina IO, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors[J].Cancer Discov,2012,2(3):270-287.
|
| [35] |
Hal EC,Anindya D,Carlos SA,et al.PHA665752,a small-molecule inhibitor of c-Met,inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met positive neuroblastoma cells[J].Bio Med Central Cancer,2009,9:411-413.
|
| [36] |
James GC,Helen YZ,Maria EA,et al.Cytoreductive antitumor activity of PF-2341066,a novel inhibitor of anaplastic lymphoma kinase and c-Met,in experimental models of anaplastic large-cell lymphoma[J].Mol Cancer Ther,2007,6(12):3314-3322.
|
| [37] |
Steinig AG.Novel 6-aminofuro[3,2-c]pyridines as potent,orally efficacious inhibitors of cMET and RON kinases[J].Bioorg Med Chem Lett,2013, 23(15):4381-4387.
|
| [38] |
Fujiwara.Quinoline derivative and quinazoline derivative inhibiting self-phosphoraylation of hepatocytus proliferator receptor and medicinal composition containning the same:US,8324245B2[P].2012-12-04[2014-10-29] .
|
| [39] |
Stephen C,Franck R,Granger MC,et al.Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases[J].Bioorg Med Chem Lett,2008,18(9):2793-2798.
|
| [40] |
Yakes FM, Jason C, Jenny T, et al. Cabozantinib(XL184), a novel MET and VEGFR2 inhibitor,simultaneously suppresses metastasis,angiogenesis,and tumor growth[J].Mol Cancer Ther,2011,10(12):2298-2308.
|
| [41] |
Qian F,Stefan E,Kyoko Y,et al.Inhibition of tumor cell growth,invasion,and metastasis by EXEL-2880(XL880,GSK1363089),a novel inhibitor of HGF and VEGF receptor tyrosine kinases[J].Cancer Res,2009,69(20):8009-8016.
|
| [42] |
Takayuki N,Osamu T,Atsumi Y,et al.E7050:a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models[J].Cancer Sci,2010,101(1):210-215.
|
| [43] |
Li S,Zhao YF,Wang KW,et al.Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors[J].Bioorg Med Chem,2013,21(11):2843-2855.
|
| [44] |
Qi BH,Mi B,Zhai X,et al.Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors[J].Bioorg Med Chem,2013,21(17):5246-5260.
|
| [45] |
Gretchen MS,An YM,Cai ZW,et al.Discovery of N-(4-(2-amino-3-chloropyridin -4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide(BMS-777607),a selective and orally efficacious inhibitor of the Met kinase superfamily[J].J Med Chem,2009,52:1251-1254.
|
| [46] |
Yoshiko A,Kazuhide N,Akio M,et al.A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities[J].Mol Cancer Ther,2013,12(6):913-924.
|
| [47] |
Yan SB,Victoria LP,Rose A,et al.LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET,MST1R,and other oncoproteins,and displays anti-tumor activities in mouse xenograft models[J].Invest New Drugs,2013,31(4):833-844.
|
| [48] |
Liu LB,Mark HN,Lee M,et al.Structure-based design of novel class II c-Met inhibitors:2.SAR and kinase selectivity profiles of the pyrazolone series[J].J Med Chem,2012,55(5):1868-1897.
|
| [49] |
She NF,Zhuo LS,Jiang W,et al.Design,synthesis and evaluation of highly selective pyridone-based class II MET inhibitors[J].Bioorg Med Chem Lett,2014,24(15):3351-3355.
|
| [50] |
Liu ZQ, Ai J, Peng X, et al. Novel 2, 4-diarylaminopyrimidine analogues(DAAPalogues)showing potent c-Met/ALK multikinase inhibitory activities[J].Med Chem Lett,2014,5(4):304-308.
|
| [51] |
Jason DK,James PJ,David JG,et al.Discovery of a 5H-benzo[4,5] cyclohepta[1,2-b] pyridin-5-one(MK-2461)inhibitor of c-Met kinase for the treatment of cancer[J].J Med Chem,2011,54(12):4092-4108.
|
| [52] |
Alan BN,Matthew HK,Michael DA,et al.Discovery of 1-[3-(1-methyl-1H-pyrazol -4-yl)-5-oxo-5H-benzo[4,5] cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide(MK-8033):a specific c-Met/RON dual kinase inhibitor with preferential affinity for the activated state of c-Met[J].J Med Chem,2013,56(6):2294-2310.
|
百度学术
下载:
